CureVac is developing an mRNA-based coronavirus vaccine, the Germany biopharma has this week confirmed.
With development efforts underway, the company says it is in contact with the Coalition for Epidemic Preparedness Innovations (CEPI) and other global organisations and authorities.
However, in a press release, the company said that it “abstains from commenting on speculations” and also “rejects allegations for acquisition of the company or its technology”.
Based on its inherent mode of action, CureVac sees mRNA as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios – such as Covid-19.
The company is leveraging its potent vaccine platform to focus on developing a potent, efficacious and safe and fast to produce vaccine against Covid-19.
It is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.
“The combination of mRNA science, disease understanding, formulation and production expertise make CureVac a unique player to fight against any infectious disease, no matter whether they are seasonal or pandemic,” said Chief Technology Officer, Mariola Fotin-Mleczek.